var data={"title":"Ramucirumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ramucirumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/731530?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ramucirumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ramucirumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24538981\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hemorrhage:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ramucirumab increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. Permanently discontinue ramucirumab in patients who experience severe bleeding.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gastrointestinal perforation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ramucirumab can increase the risk of gastrointestinal perforation, a potentially fatal event. Permanently discontinue ramucirumab in patients who experience a gastrointestinal perforation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Wound healing impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Impaired wound healing can occur with antibodies inhibiting the VEGF pathway. Discontinue ramucirumab therapy in patients with impaired wound healing. Withhold ramucirumab prior to surgery and discontinue ramucirumab if a patient develops wound healing complications.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674213\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cyramza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45617145\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cyramza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24538987\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody;</li>\n      <li>\n        Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674231\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedicate prior to infusion with an IV H<sub>1</sub> antagonist (for patients who experienced a grade 1 or 2 infusion reaction with a prior infusion, also premedicate with dexamethasone or equivalent and acetaminophen).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Colorectal cancer, metastatic:</b> IV: 8 mg/kg every 2 weeks in combination with FOLFIRI (irinotecan, leucovorin, and fluorouracil); continue until disease progression or unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric cancer, advanced or metastatic:</b> IV: 8 mg/kg every 2 weeks as a single agent or in combination with paclitaxel; continue until disease progression or unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer, metastatic:</b> IV: 10 mg/kg on day 1 every 21 days in combination with docetaxel; continue until disease progression or unacceptable toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674269\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674270\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674271\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (normal bilirubin with AST &gt; ULN <b>or</b> total bilirubin &gt;1 to 1.5 times ULN and any AST): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (total bilirubin &gt;1.5 to 3 times ULN and any AST): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (total bilirubin &gt;3 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use in patients with Child-Pugh class B or C cirrhosis only if the potential benefits outweigh the potential risks. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674272\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Infusion-related reaction:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Grade 1 or 2: Reduce infusion rate by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Grade 3 or 4: Permanently discontinue </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Hypertension:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe hypertension: Interrupt infusion until controlled with medical management</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe hypertension, uncontrolled: Permanently discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Proteinuria:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Urine protein &ge;2 g/24 hours (first dose reduction): Withhold treatment; when urine protein returns to &lt;2 g/24 hours, reinitiate at a reduced dose of 6 mg/kg (if initial dose was 8 mg/kg) or 8 mg/kg (if initial dose was 10 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Recurrent urine protein &ge;2 g/24 hours (second dose reduction): Withhold treatment; when urine protein returns to &lt;2 g/24 hours, reinitiate at a reduced dose of 5 mg/kg (if first dose reduction was to 6 mg/kg) or 6 mg/kg (if first dose reduction was to 8 mg/kg) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Urine protein &gt;3 g/24 hours: Discontinue permanently</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nephrotic syndrome: Discontinue permanently</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Arterial thrombotic events:</i> Discontinue permanently</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Bleeding, grade 3 or 4:</i> Discontinue permanently</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Gastrointestinal perforation:</i> Discontinue permanently</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Reversible posterior leukoencephalopathy syndrome (RPLS):</i> Discontinue permanently for confirmed diagnosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Wound healing complications:</i> Withhold treatment prior to surgery; do not reinitiate until the surgical wound is fully healed. If wound healing complications develop during treatment, withhold ramucirumab until the wound is fully healed.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24744786\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyramza: 100 mg/10 mL (10 mL); 500 mg/50 mL (50 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674215\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674274\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Premedicate prior to infusion with an IV H<sub>1</sub> antagonist; for patients who experienced a grade 1 or 2 infusion reaction with a prior infusion, also premedicate with dexamethasone (or equivalent) and acetaminophen.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infuse over 60 minutes through a separate infusion line using an infusion pump; the use of a 0.22 micron protein sparing filter is recommended. Do not administer as an IV push or bolus. Flush the line with NS after infusion is complete. Do not infuse in the same IV line with electrolytes or other medications. Administer ramucirumab prior to docetaxel, paclitaxel, or FOLFIRI if administering in combination. Monitor for infusion reaction; reduce infusion rate (by 50%) for grade 1 or 2 infusion reaction; discontinue permanently for grade 3 or 4 infusion reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24538984\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic:</b> Treatment (in combination with FOLFIRI [irinotecan, leucovorin, and fluorouracil]) of metastatic colorectal cancer (mCRC) in patients with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric cancer, advanced or metastatic:</b> Treatment (single-agent or in combination with paclitaxel) of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients with disease progression on or following fluoropyrimidine- or platinum-containing chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer, metastatic:</b> Treatment (in combination with docetaxel) of metastatic non-small cell lung cancer (NSCLC) in patients with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674212\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cyramza may be confused with Cimzia</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ramucirumab may be confused with ranibizumab, rituximab, regorafenib</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24656307\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported with monotherapy. Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension (16%; grades 3/4: 8%), arterial thrombosis (including myocardial infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia; 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (9%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyponatremia (6%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (14%), intestinal obstruction (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Proteinuria (8% to 17%; grade &ge;3: 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased red blood cells (requiring transfusion; 11%), neutropenia (5%), anemia (4%), hemorrhage (2% to 4%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (3%; neutralizing: 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Infusion related reaction (&le;16%; reactions minimized with premedications) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1% and frequency not defined: Gastrointestinal perforation, reversible posterior leukoencephalopathy syndrome </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24547989\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to ramucirumab or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674221\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arterial thrombotic events: Serious and fatal arterial thrombotic events, including MI, cardiac arrest, cerebrovascular accident, and cerebral ischemia, have occurred with ramucirumab. Discontinue permanently in patients who experience serious arterial thrombotic events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression:  A higher incidence of neutropenia and thrombocytopenia were observed when ramucirumab was used in combination with paclitaxel (compared to paclitaxel with placebo); monitor CBC with differential when used in combination with paclitaxel. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal perforation: <b>[US Boxed Warning]: Ramucirumab may increase the risk of gastrointestinal perforation, a potentially fatal event. Discontinue permanently in patients who experience a gastrointestinal perforation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemorrhage: <b>[US Boxed Warning]: Ramucirumab is associated with an increased risk of hemorrhage and gastrointestinal hemorrhage, which may be severe or sometimes fatal. Discontinue ramucirumab permanently in patients who experience serious bleeding.</b>  Patients receiving NSAIDs were excluded from some clinical trials; the risk of gastric hemorrhage in patients with gastric tumors receiving NSAIDs is not known. In addition, NSCLC patients receiving therapeutic anticoagulation or chronic NSAID or other antiplatelet therapy (other than aspirin), or with radiograph evidence of major airway or blood vessel involvement or intratumor cavitation were also excluded from the clinical study; the risk of pulmonary hemorrhage in such patients is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertension: May cause and/or worsen hypertension; the incidence of severe hypertension is increased with ramucirumab. Blood pressure (BP) should be controlled prior to treatment initiation. Monitor BP every 2 weeks (more frequently if indicated) during treatment. If severe hypertension occurs, temporarily withhold until medically controlled. Discontinue permanently if medically significant hypertension cannot be controlled with antihypertensive therapy or in patients with hypertensive crisis or hypertensive encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infusion reaction: Ramucirumab is associated with infusion-related reactions (may be severe), generally occurring with the first or second dose. Symptoms of infusion reactions have included chills, flushing, hypotension, bronchospasm, dyspnea, hypoxia, wheezing, chest pain/tightness, supraventricular tachycardia, back pain/spasms, rigors/tremors, and/or paresthesia. Monitor for infusion reaction symptoms during infusion; discontinue immediately and permanently for grade 3 or 4 infusion reactions.  Administer in a facility equipped to manage infusion reactions. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Proteinuria/nephrotic syndrome: Ramucirumab is associated with proteinuria (may be severe). Monitor proteinuria during treatment by urine dipstick and/or urinary protein creatinine ratio for the development of and/or worsening of proteinuria. Withhold treatment for urine protein levels &ge;2 g/24 hours. Discontinue permanently for urine protein &gt;3 g/24 hours or for nephrotic syndrome. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Reversible posterior leukoencephalopathy syndrome: Cases of reversible posterior leukoencephalopathy syndrome (RPLS) have been reported (may be fatal). Symptoms of RPLS include headache, seizure, confusion, lethargy, blindness and/or other vision, or neurologic disturbances. Confirm diagnosis of RPLS with MRI; discontinue ramucirumab with confirmed RPLS diagnosis. Resolution of symptoms may occur within days after discontinuation, although neurologic sequelae may remain in some patients. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid dysfunction: Hypothyroidism has been observed. Monitor thyroid function during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Wound healing impairment: <b>[US Boxed Warning]: Impaired wound healing can occur with antibodies inhibiting the VEGF pathway. Discontinue ramucirumab in patients with impaired wound healing. Withhold ramucirumab prior to surgery and discontinue in patients who develop wound healing complications.</b> Following surgery, use clinical judgment to resume based on adequate wound healing. If wound healing complications develop during treatment, withhold ramucirumab until wound is fully healed. Ramucirumab was not studied in patients with serious or nonhealing wounds.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Antiangiogenic medications may increase the risk for heart failure (HF); events consistent with HF have been reported with ramucirumab. Use with caution in patients with known (or at risk of) coronary artery disease. Ramucirumab may enhance the cardiotoxicity of other chemotherapy with cardiotoxic potential (Cyramza Canadian labeling 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Clinical deterioration, including new onset or worsening encephalopathy, ascites, or hepatorenal syndrome has been reported in patients with Child-Pugh class B or C cirrhosis receiving ramucirumab. Use in patients with Child-Pugh class B or C cirrhosis only if the potential benefits outweigh the potential risks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674185\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674182\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=94963&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674218\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Ramucirumab inhibits angiogenesis, which is of critical importance to human fetal development. Based on the mechanism of action, ramucirumab may cause fetal harm if administered during pregnancy. Women of reproductive potential should use effective contraception during and for at least 3 months after the last ramucirumab dose. Ramucirumab may impair fertility in women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674220\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ramucirumab is excreted in breast milk. Immunoglobulins are excreted in breast milk, and it is assumed that ramucirumab may appear in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674277\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests; urine protein (by urine dipstick and/or urinary protein creatinine ratio); thyroid function; CBC with differential (when used as a part of combination chemotherapy); blood pressure (every 2 weeks; more frequently if indicated); signs/symptoms of infusion-related reactions (during infusion); signs/symptoms of arterial thromboembolic events, bleeding/hemorrhage, gastrointestinal perforation, wound healing impairment, and reversible posterior leukoencephalopathy syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674226\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ramucirumab is a recombinant monoclonal antibody which inhibits vascular endothelial growth factor receptor 2 (VEGFR2). Ramucirumab has a high affinity for VEGFR2 (Spratlin, 2010), binding to it and blocking binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D to inhibit activation of VEGFR2, thereby inhibiting ligand-induced proliferation and migration of endothelial cells. VEGFR2 inhibition results in reduced tumor vascularity and growth (Fuchs, 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674228\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Half-life elimination: 14 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24942719\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cyramza Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/10 mL (10 mL): $1,331.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/50 mL (50 mL): $6,658.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45783789\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cyramza (AT, AU, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, IE, IL, JP, KR, LT, LU, MY, NO, PL, PT, RO, SE, SG, SI, SK, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cyramza (ramucirumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cyramza (ramucirumab) [product monograph]. Toronto, Ontario: Eli Lilly Canada; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet</i>. 2014;383(9911):31-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ramucirumab-drug-information/abstract-text/24094768/pubmed\" target=\"_blank\" id=\"24094768\">24094768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicenter, double-blind, randomized phase 3 trial. <i>Lancet</i>. 2014;384(9944):665-673.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ramucirumab-drug-information/abstract-text/24933332/pubmed\" target=\"_blank\" id=\"24933332\">24933332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. <i>J Clin Oncol</i>. 2010;28(5):780-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ramucirumab-drug-information/abstract-text/20048182/pubmed\" target=\"_blank\" id=\"20048182\">20048182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study [published online April 12, 2015]. <i>Lancet Oncol</i>. 2015;16(5):499-508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ramucirumab-drug-information/abstract-text/25877855/pubmed\" target=\"_blank\" id=\"25877855\">25877855</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilke H, Muro K, Van Cutsem E, et al; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncol</i>. 2014;15(11):1224-1235.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ramucirumab-drug-information/abstract-text/25240821/pubmed\" target=\"_blank\" id=\"25240821\">25240821</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 94963 Version 68.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F24538981\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24674213\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45617145\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F24538987\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F24674231\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F24674269\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F24674270\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F24674271\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F24674272\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24744786\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F24674215\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24674274\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F24538984\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F24674212\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F24656307\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F24547989\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F24674221\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F24674185\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F24674182\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F24674218\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F24674220\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24674277\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F24674226\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F24674228\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F24942719\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45783789\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/94963|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ramucirumab-patient-drug-information\" class=\"drug drug_patient\">Ramucirumab: Patient drug information</a></li></ul></div></div>","javascript":null}